Along this line, we identified a druggable allosteric pocket nearby the K700E mutation in SF3B1 (Figure S5), which may be exploited in future structure-based drug discovery studies aimed at devising novel inhibitory strategies to selectively target SF3b containing the most frequent mutations in patients affected by hematologic malignancies. Here, SF3B1 is linked to hematologic disorder.